Clinical trials: Human Cancers
Oropharyngeal Squamous Cell Carcinoma
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Pembrolizumab and nivolumab (with or without chemotherapy) are used to treat head and neck cancer. The middle part of the throat (oropharynx) is a common location for head and neck cancer.
- Trial name
- NCT06771674
- Testing
- Pembrolizumab, Nivolumab
- Where
- United States
- Volunteers
- 662 people
- Sponsor
- Hookipa Biotech GmbH
Human Papillomavirus-Related Cervical Carcinoma
Self-Collection for Cervical Cancer Screening and HPV Vaccination for Cancer Prevention Among Women in Emergency Care in Northeast Florida
Human Papilloma Virus (HPV) is a cause of cervical cancer in women. This study is being done to identify sites for cervical cancer screening and education regarding HPV vaccination outside of the traditional settings of primary…
- Trial name
- NCT06607874
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx
Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer
This phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus…
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Trial name
- OPTIMA (NCT02258659)
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, radiation therapy
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Chicago
Advanced Solid Tumors
Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib
This is a non-randomised study in patients with advanced solid malignancies
- Trial name
- ADME (NCT05008913)
- Testing
- [14C]Adavosertib
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
Melanoma
Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
The main goal of this study is to test if it is safe and effective to give CDX-3379 together to treat advanced melanoma in patients with the NRAS mutation and BRAF/NRAS wildtype.
- Trial name
- NCT03580382
- Testing
- Trametinib daily Until PD, CDX-3379 (ERBB3 antibody)
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- NYU Langone Health
Leukemia, Lymphoma
CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
Patients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient, which can be genetically…
- Trial name
- NCT03684889
- Testing
- SCRI-huCAR19v1, SCRI-huCAR19v2
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Seattle Children's Hospital
Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer
A Study of ZW251 in Participants With Advanced Solid Tumors
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell…
- Conditions
- Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
- Trial name
- NCT07164313
- Testing
- ZW251
- Where
- 25 sites in United States, Ireland and 4 more
- Volunteers
- 140 people
- Sponsor
- Zymeworks BC Inc.
Metastatic Castration Resistant Prostate Cancer
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
This clinical trial is evaluating a drug called AC176 in participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least two prior systemic therapies.
- Trial name
- NCT05241613
- Testing
- AC176
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Accutar Biotechnology Inc
Recurrent/Advanced Gastric Cancer
Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression
Clinical Indication : HER mutated or HER2 Amplification/Overexpression in Gastric Cancer, 2nd-line Trial Type : Interventional, Open label Treatment Groups : Single arm: Pembrolizumab 200 mg every 3 weeks (Q3W), neratinib at 240…
- Trial name
- NCT05512182
- Testing
- Chemotherapy
- Where
- South Korea
- Sponsor
- Yonsei University
Colorectal Neoplasm
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)
The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.
- Trial name
- NCT03384940
- Testing
- DS-8201a
- Where
- 25 sites in United States, Italy and 3 more
- Volunteers
- 86 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Hepatitis C, Hepatocellular Carcinoma
STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention for Elevated LFTs
The investigators will conduct a randomized controlled trial comparing two strategies to promote HCV screening, follow-up testing, and treatment among Parkland patients who are 18 years or older who have elevated liver…
- Trial name
- STOP-HCC (NCT04395118)
- Testing
- Mailed Outreach
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Moderate and Severe RheumatoId Arthritis
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
The purpose of this study is to initially access the safety and effectivity of RC18 combined with methotrexate (MTX) in comparison with the use of methotrexate alone in participants with moderate to severe Rheumatoid Arthritis…
- Trial name
- NCT03016013
- Testing
- RC18 160 mg plus MTX
- Where
- China
- Volunteers
- 479 people
- Sponsor
- RemeGen Co., Ltd.
Nonmalignant Neoplasm, Prostate Cancer
Lycopene in Treating Patients With Prostate Cancer or Benign Prostatic Hyperplasia
RATIONALE: Chemoprevention is the use of certain substances to keep cancer from forming, growing, or coming back. Eating a diet high in lycopene, a substance found in tomatoes and tomato products, may keep cancer from forming or…
- Trial name
- NCT00416390
- Testing
- lycopene, laboratory biomarker analysis, biopsy
- Volunteers
- 120 people
- Sponsor
- University of Illinois Chicago
Recurrent Respiratory Papillomatosis, Papillomavirus Infections
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
This is a Phase 1/2 study in patients with a Recurrent Respiratory Papillomatosis (RRP) disease burden that requires repeated surgical procedures for management. RRP is a rare disease caused by the human papillomavirus (HPV).
- Conditions
- Recurrent Respiratory Papillomatosis, Papillomavirus Infections, Papillomaviridae
- Trial name
- NCT04724980
- Testing
- PRGN-2012 - Phase I; Dose Level 1, PRGN-2012 - Phase I; Dose Level 2, PRGN-2012 - Phase II; Dose Level 2
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Precigen, Inc
Leukemia, Lymphocytic
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
Background: Chronic lymphocytic leukemia (CLL) is a blood cancer. Recombinant human interleukin 15 (IL-15) is a manmade protein. Obinutuzumab is a protein made to deactivate cancer cells.
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Trial name
- NCT03759184
- Testing
- rhIL-15, Obinutuzumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Intraepithelial Neoplasia
Cervical And Self-Sample In Screening Study
The proposed study seeks to compare the diagnostic performance of Human Papillomavirus (HPV) testing in self-collected samples via the Eve Medical self-collection system© (Eve) with standard physician-collected samples for the…
- Trial name
- CASSIS (NCT02397252)
- Testing
- Eve Medical self-collection system©, cobas® PCR Female swab self-sampling, Physician-collected sampling
- Where
- Canada
- Volunteers
- 1,225 people, healthy volunteers welcome
- Sponsor
- McGill University
Cancer Pain
Human Physiology and Self-Reported Pain Score
To assess whether the patient's self-reported pain level is associated with a multivariate physiological biomarker bias achieved in the actual clinical setting.
- Trial name
- NCT04053608
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Taichung Veterans General Hospital
Cancer of Cervix
Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients
The propose of this study is to determine if neoadjuvant chemotherapy followed by chemoradiation is safe and effective in locally advanced cervical cancer patients.
- Trial name
- NCT02309658
- Testing
- gemcitabine, cisplatin, chemoradiation
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Professor Fernando Figueira Integral Medicine Institute
HPV
Self-sampling for Human Papillomavirus (HPV) Among Patients Receiving Colposcopy
This study seeks to compare the accuracy and acceptability of HPV testing self-sampling kit and standard clinician-sampling for HPV testing.
- Trial name
- NCT04585243
- Testing
- Evalyn Brush
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Milton S. Hershey Medical Center
Multiple Myeloma, Neoplasm, Plasma Cell
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT).
- Conditions
- Multiple Myeloma, Neoplasm, Plasma Cell, Neoplasms by Histologic Type, Neoplasms
- Trial name
- NCT04309084
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Celularity Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.